However, in lung cancer, where KMT2D was found to be the most highly inactivated epigenetic modifier, KMT2D-inactivating mutations induce aberrant metabolic reprogramming via increased expression of glycolytic genes (Alam et al., 2020). This evidence concerns the gene KMT2D and lung carcinoma.